GenSight Biologics Announces the Filing of its 2025 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026

GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising

GenSight Biologics Announces Successful Fundraising Worth Nearly €1.7 Million

GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study

GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments

The 15-20 National Hospital and GenSight Biologics announce the treatment of the first patient in the GS010/LUMEVOQ® REVISE Study